Seres Therapeutics, Inc. (MCRB) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
MCRB EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
MCRB Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | -423.8% | -11910.1% | 721.9% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | 100.0% | -44.5% | -45.2% |
Download Data
Export MCRB earnings history in CSV or JSON format
Free sign-in required to download data
Seres Therapeutics, Inc. (MCRB) Earnings Overview
As of May 8, 2026, Seres Therapeutics, Inc. (MCRB) reported trailing twelve-month net income of -$47M, reflecting +103.4% year-over-year growth. The company earned $-4.89 per diluted share over the past four quarters, with a net profit margin of 721.9%.
Looking at the long-term picture, MCRB's historical earnings data spans multiple years. The company achieved its highest annual net income of $6M in fiscal 2025, representing a new all-time high.
Seres Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$164M net income, -297.1% margin), MIRM (-$799M net income, -4.5% margin), ARWR (-$301M net income, -0.2% margin), MCRB has outperformed on profitability metrics. Compare MCRB vs NKTR →
MCRB Earnings vs Peers
Earnings metrics vs comparable public companies
MCRB Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $6M | +4088.2% | -$94M | $0.64 | 721.9% | -11910.1% |
| 2024 | $136,000 | +100.1% | -$121M | $-18.86 | - | - |
| 2023 | -$114M | +54.5% | -$195M | $-17.77 | - | - |
| 2022 | -$250M | -281.5% | -$180M | $-46.29 | - | - |
| 2021 | -$66M | +26.4% | -$64M | $-14.30 | -45.2% | -44.5% |
| 2020 | -$89M | -26.8% | -$88M | $-22.34 | -268.3% | -265.3% |
| 2019 | -$70M | +29.0% | -$72M | $-24.81 | -203.7% | -208.3% |
| 2018 | -$99M | -10.7% | -$100M | $-48.57 | -350.0% | -354.8% |
| 2017 | -$89M | +2.4% | -$91M | $-44.19 | -278.4% | -284.7% |
| 2016 | -$92M | -67.2% | -$93M | $-46.00 | -420.7% | -426.5% |
See MCRB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MCRB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MCRB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMCRB — Frequently Asked Questions
Quick answers to the most common questions about buying MCRB stock.
Is MCRB growing earnings?
MCRB EPS is $-4.89, with earnings growth accelerating to +103.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-47M.
What are MCRB's profit margins?
Seres Therapeutics, Inc. net margin is +721.9%, with operating margin at -11910.1%. Above-average margins indicate pricing power.
How consistent are MCRB's earnings?
MCRB earnings data spans 2012-2025. The accelerating earnings trend is +103.4% YoY. Historical data enables comparison across business cycles.